PMID- 33652059
OWN - NLM
STAT- MEDLINE
DCOM- 20210520
LR  - 20210520
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 899
DP  - 2021 May 15
TI  - Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a 
      meta-analysis.
PG  - 173985
LID - S0014-2999(21)00138-2 [pii]
LID - 10.1016/j.ejphar.2021.173985 [doi]
AB  - This meta-analysis evaluated the efficacy and safety of infliximab as initial 
      therapy for patients with Kawasaki disease (KD) and intravenous immunoglobulin 
      (IVIG) resistant KD. Studies of infliximab in KD, published between January 2004 
      and December 2019, were curated from PubMed, MEDLINE, and Cochrane Library. Data 
      were analyzed using STATA Version 12.0. Of the 8 studies considered, 4 evaluated 
      the effect of infliximab combined with IVIG as primary therapy in KD, and the 
      remaining investigated the effect of infliximab in IVIG resistant patients. 
      Infliximab was more effective than the control group, with the total summary odds 
      ratio (OR) of 0.34 (95% confidence interval (CI): 0.19-0.62). The treatment 
      resistance of the infliximab group was lower than the IVIG group (0.36 [95% CI: 
      0.14-0.92]) when infliximab was combined with IVIG as the initial treatment. 
      However, infliximab treatment for IVIG resistant KD was more effective than the 
      IVIG group (0.28 [95% CI: 0.12-0.66]). There was no significant increase in the 
      incidence of coronary artery lesions. The total summary OR for the incidence of 
      coronary artery lesions and infliximab treatment was 0.88 (95% CI: 0.48-1.62). 
      There was no statistically significant difference in adverse events (AEs) when 
      compared between the groups (0.71 [95% CI: 0.44-1.16]). Infliximab combined with 
      IVIG reduced treatment resistance in KD patients vs. conventional IVIG therapy. 
      Infliximab improved clinical course in IVIG resistant KD patients. Infliximab 
      treatment did not reduce the incidence of coronary artery lesions and did not 
      show any significant increase in the incidence of AEs. PROSPERO REGISTRATION 
      NUMBER: CRD42020218554.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Li, Xuan
AU  - Li X
AD  - Department of Cardiology, Children's Hospital of Soochow University, Suzhou, 
      215003, China. Electronic address: 879991662@qq.com.
FAU - Tang, Yunjia
AU  - Tang Y
AD  - Department of Cardiology, Children's Hospital of Soochow University, Suzhou, 
      215003, China. Electronic address: 824432264@qq.com.
FAU - Ding, Yueyue
AU  - Ding Y
AD  - Department of Cardiology, Children's Hospital of Soochow University, Suzhou, 
      215003, China. Electronic address: dyy79qd@hotmail.com.
FAU - Chen, Ye
AU  - Chen Y
AD  - Department of Cardiology, Children's Hospital of Soochow University, Suzhou, 
      215003, China. Electronic address: chenye20080921@sina.com.
FAU - Hou, Miao
AU  - Hou M
AD  - Department of Cardiology, Children's Hospital of Soochow University, Suzhou, 
      215003, China. Electronic address: houmiao321@126.com.
FAU - Sun, Ling
AU  - Sun L
AD  - Department of Cardiology, Children's Hospital of Soochow University, Suzhou, 
      215003, China. Electronic address: Sunny70mail@163.com.
FAU - Qian, Guanghui
AU  - Qian G
AD  - Institute of Pediatric Research, Children's Hospital of Soochow University, 
      China. Electronic address: guanghui_qian@163.com.
FAU - Qin, Liqiang
AU  - Qin L
AD  - Department of Nutrition and Food Hygiene, School of Public Health, Soochow 
      University, Suzhou, China. Electronic address: qinliqiang@suda.edu.cn.
FAU - Lv, Haitao
AU  - Lv H
AD  - Department of Cardiology, Children's Hospital of Soochow University, Suzhou, 
      215003, China. Electronic address: haitaosz@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210227
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Drug Resistance
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/adverse effects/*therapeutic use
MH  - Immunologic Factors/adverse effects/*therapeutic use
MH  - Infant
MH  - Infliximab/adverse effects/*therapeutic use
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/diagnosis/*drug therapy/immunology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Infliximab
OT  - Intravenous immunoglobulin
OT  - Kawasaki disease
OT  - Meta-analysis
EDAT- 2021/03/03 06:00
MHDA- 2021/05/21 06:00
CRDT- 2021/03/02 20:08
PHST- 2020/10/03 00:00 [received]
PHST- 2021/02/13 00:00 [revised]
PHST- 2021/02/23 00:00 [accepted]
PHST- 2021/03/03 06:00 [pubmed]
PHST- 2021/05/21 06:00 [medline]
PHST- 2021/03/02 20:08 [entrez]
AID - S0014-2999(21)00138-2 [pii]
AID - 10.1016/j.ejphar.2021.173985 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2021 May 15;899:173985. doi: 10.1016/j.ejphar.2021.173985. Epub 
      2021 Feb 27.